Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma

Abstract

Background: Recently, FAM83H was reported to have roles in cancer progression in conjunction with oncogenic molecules such as MYC and b-catenin. Moreover, the data from the public database indicates a molecular relationship between FAM83H and zinc finger proteins, especially between FAM83H and ZNF16. However, studies on FAM83H and ZNF16 in gallbladder cancer have been limited. Methods: This study investigated the expression of FAM83H and ZNF16 in 105 gallbladder carcinomas. Results: In human gallbladder carcinomas, immunohistochemical expression of FAM83H was significantly associated with ZNF16 expression. In univariate analysis, nuclear and cytoplasmic expression of FAM83H or ZNF16 were significantly associated with shorter survival of gallbladder carcinoma patients. Multivariate analysis revealed the nuclear expression of FAM83H as an independent indicator of poor prognosis of overall survival (p = 0.005) and relapse-free survival (p = 0.005) of gallbladder carcinoma patients. Moreover, co-expression patterns of nuclear FAM83H and ZNF16 were also independent indicators of shorter survival of gallbladder carcinoma patients (overall survival; p < 0.001, relapse-free survival; p < 0.001). Conclusions: This study suggests FAM83H and ZNF16 are associated with the progression of gallbladder carcinoma, and the expressions of FAM83H and ZNF16 might be novel prognostic indicators of gallbladder carcinoma patients.

SCRIB Is Involved in the Progression of Ovarian Carcinomas in Association with the Factors Linked to Epithelial-to-Mesenchymal Transition and Predicts Shorter Survival of Diagnosed Patients

“…The immunohistochemical positivity of the nuclear expression of SCRIB (nSCRIB) and cytoplasmic expression of SCRIB (cSCRIB) was determined by receiver operating characteristic (ROC) curve analysis [ 25 ]. The cut-off points in ROC curve analysis for nSCRIB and cSCRIB were determined to predict the cancer-related death of patients [ 10 , 25 , 26 ]. The prognosis of ovarian carcinoma patients was evaluated for overall survival (OS) and relapse-free survival (RFS) through June 2015.…”

Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma

“…The immunohistochemical expression of SIRT6 was scored by adding the staining intensity score and staining area score. The staining intensity was scored from zero to three (0; no expression, 1; weak expression, 2; intermediate expression, and 3; strong expression), and the staining area was scored from zero to five (0: no stained cells; 1: 1%, 2: 2 ~ 10%, 3: 11 ~ 33%; 4: 34 ~ 66%; and 5: 67 ~ 100%) [ 10 , 31 , 37 – 39 ]. Thereafter, the final immunohistochemical staining score was obtained by adding the scores obtained from each TMA core, which ranged from zero to sixteen [ 38 , 39 ].…”

Inhibition of SIRT6 Potentiates the Anti-Tumor Effect of Doxorubicin through Suppression of the DNA Damage Repair Pathway in Osteosarcoma

“…The immunohistochemical expression of SIRT6 was scored by adding the staining intensity score and staining area score. The staining intensity was scored from zero to three (0; no expression, 1; weak expression, 2; intermediate expression, and 3; strong expression) and the staining area was scored from zero to ve (0: no expression; 1: weak expression; 2: intermediate expression; and 3: strong expression) and the staining area was scored from zero to ve (0: no stained cells; 1: 1%, 2: 2 ~ 10%, 3: 11 ~ 33%; 4: 34 ~ 66%; and 5: 67 ~ 100%) [10,31,[37][38][39]. Thereafter, the nal immunohistochemical staining score was obtained by adding the scores obtained from each TMA core, which ranged from zero to sixteen [38,39].…”